Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
about
DNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting DNA damage response in cancer therapyTherapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerThe critical role of Akt in cardiovascular functionPI3K and cancer: lessons, challenges and opportunitiesIdentification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.Proteomic Identification of DNA-PK Involvement within the RET Signaling Pathway.Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.DNA-dependent protein kinase and its inhibition in support of radiotherapy.Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer.Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing.Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair.Precision genome editing in the CRISPR era.Targeting DNA-Dependent Protein Kinase for Cancer Therapy.Delineation of key XRCC4/Ligase IV interfaces for targeted disruption of non-homologous end joining DNA repair.TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiationChemo-sensitisation of HeLa cells to etoposide by a benzoxazine in the absence of DNA-PK inhibition.Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes.Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.Integrated multi-omics data analysis identifying novel drug sensitivity-associated molecular targets of hepatocellular carcinoma cells.The road less traveled: strategies to enhance the frequency of homology-directed repair (HDR) for increased efficiency of CRISPR/Cas-mediated transgenesis
P2860
Q26768679-7278F5A9-A56C-4879-BEB0-FE12DADC1521Q26776513-0A46164A-4E56-4E2E-B596-43355E112D29Q27023204-CD037C8E-CFB1-4E6A-BD75-FDA71A7457A8Q27852340-4A865BB5-0851-458D-A129-6CF6E370D837Q28066320-9C4300BA-DD29-498F-BA67-34567FCCFDF7Q28083829-A02DF52C-B0AE-4F4B-8C20-8CFA5FF68B98Q30080017-9D4C5EE0-CA36-47A0-AF37-BB88D583E597Q33709701-7EBB7AC7-881B-4901-97F5-CBF3B0258345Q35059927-C87DE147-29D1-4635-857B-877E675CCC2CQ35103519-B3515B5A-7F6F-47DA-B2C0-C8C9E7489B4CQ35660873-D033C8FE-0C94-4BB2-8257-CFCF8A84C498Q36544857-26DD207A-DC0F-4FB9-B328-294650E87094Q37086196-B4A3CF5B-9FE8-462F-9504-B9140547129BQ37122690-AAECAF66-5F70-448F-B074-D3A6007C4D3CQ37626600-81E795F5-C7CB-44B8-9CAB-DC7E8C3D3B06Q38077808-73B0BCD4-E107-449C-92FC-3B05A569BEF3Q38608688-DA6BB33C-90DE-4B91-9017-260249EE58F0Q38690281-7003E2E0-0B4F-4865-A351-560A68EF2930Q38712083-C98FEFD3-201D-46DB-8C52-6CA5B579CB59Q38840857-3F9E5D6D-935C-42D7-B99E-67FA9500FDB0Q39015702-E89B88E1-C361-4BE9-A1E8-BD60346AB062Q39126189-6FA1FBF3-FBEE-446F-8B60-DEEA27BB7308Q39250742-6CB59234-05D3-4B6B-A1A6-E59249126D2AQ39398108-ED1F0A26-B9E0-47F2-9CE3-A92DE8E3A0EBQ40854245-1B19D757-116B-4F9A-9965-4839FA0CB4F8Q41832240-DCE36878-056F-42AF-AE2A-4A4B285707AFQ42316990-CFC04FD3-1357-4845-94C5-167335A7D6CEQ47710977-1E20C704-DB19-41C0-B0B1-89EDE1565DC8Q52720061-B3AC5CD6-A494-454D-84B0-59EFFA807B88Q55100687-1AE08531-287C-4A44-A16F-6C66BEBA8932Q55396493-EA588793-C0B5-464D-ADBA-599DC033B2FFQ58795260-A077C7B3-E831-4E38-96AA-85330DD8EDDF
P2860
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
@ast
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
@en
type
label
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
@ast
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
@en
prefLabel
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
@ast
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
@en
P2093
P2860
P1476
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
@en
P2093
Andrew Slade
Caroline J Richardson
Celine Cano
David R Newell
Graeme C M Smith
Helen Jenkins
Joanne M Munck
Jody Barbeau
Julia Bardos
Keith Menear
P2860
P304
P356
10.1158/1535-7163.MCT-11-0535
P577
2012-05-10T00:00:00Z